<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p88" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_88{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t2_88{left:341px;bottom:30px;}
#t3_88{left:348px;bottom:25px;letter-spacing:0.11px;}
#t4_88{left:377px;bottom:30px;}
#t5_88{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t6_88{left:540px;bottom:30px;}
#t7_88{left:546px;bottom:25px;letter-spacing:0.07px;}
#t8_88{left:44px;bottom:77px;letter-spacing:0.1px;word-spacing:-0.05px;}
#t9_88{left:44px;bottom:63px;letter-spacing:0.1px;}
#ta_88{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#tb_88{left:285px;bottom:827px;letter-spacing:-0.29px;}
#tc_88{left:996px;bottom:873px;letter-spacing:-0.1px;}
#td_88{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#te_88{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#tf_88{left:1130px;bottom:28px;letter-spacing:0.17px;}
#tg_88{left:36px;bottom:166px;}
#th_88{left:46px;bottom:160px;letter-spacing:0.13px;}
#ti_88{left:261px;bottom:160px;}
#tj_88{left:36px;bottom:149px;}
#tk_88{left:42px;bottom:143px;letter-spacing:0.13px;word-spacing:-0.06px;}
#tl_88{left:310px;bottom:143px;}
#tm_88{left:36px;bottom:132px;}
#tn_88{left:42px;bottom:127px;letter-spacing:0.13px;word-spacing:-0.03px;}
#to_88{left:45px;bottom:110px;letter-spacing:0.14px;}
#tp_88{left:406px;bottom:110px;}
#tq_88{left:36px;bottom:523px;letter-spacing:-0.15px;word-spacing:0.06px;}
#tr_88{left:36px;bottom:505px;letter-spacing:-0.09px;}
#ts_88{left:36px;bottom:487px;letter-spacing:-0.11px;}
#tt_88{left:405px;bottom:778px;letter-spacing:0.29px;word-spacing:-0.13px;}
#tu_88{left:646px;bottom:778px;letter-spacing:0.29px;}
#tv_88{left:646px;bottom:760px;letter-spacing:0.3px;}
#tw_88{left:828px;bottom:778px;letter-spacing:0.34px;}
#tx_88{left:405px;bottom:665px;letter-spacing:-0.1px;}
#ty_88{left:485px;bottom:672px;}
#tz_88{left:278px;bottom:665px;letter-spacing:-0.11px;}
#t10_88{left:645px;bottom:701px;letter-spacing:-0.09px;}
#t11_88{left:645px;bottom:683px;letter-spacing:-0.1px;}
#t12_88{left:783px;bottom:691px;}
#t13_88{left:645px;bottom:665px;}
#t14_88{left:645px;bottom:646px;letter-spacing:-0.09px;}
#t15_88{left:645px;bottom:628px;letter-spacing:-0.1px;}
#t16_88{left:753px;bottom:636px;}
#t17_88{left:278px;bottom:580px;letter-spacing:-0.09px;}
#t18_88{left:278px;bottom:561px;letter-spacing:-0.11px;}
#t19_88{left:405px;bottom:598px;letter-spacing:-0.08px;word-spacing:-0.01px;}
#t1a_88{left:405px;bottom:580px;letter-spacing:-0.1px;}
#t1b_88{left:405px;bottom:561px;letter-spacing:-0.09px;}
#t1c_88{left:405px;bottom:543px;letter-spacing:-0.1px;}
#t1d_88{left:545px;bottom:551px;}
#t1e_88{left:645px;bottom:573px;letter-spacing:-0.1px;}
#t1f_88{left:784px;bottom:580px;}
#t1g_88{left:645px;bottom:554px;}
#t1h_88{left:645px;bottom:536px;letter-spacing:-0.09px;}
#t1i_88{left:645px;bottom:518px;letter-spacing:-0.1px;}
#t1j_88{left:753px;bottom:525px;}
#t1k_88{left:278px;bottom:451px;letter-spacing:-0.11px;}
#t1l_88{left:278px;bottom:313px;letter-spacing:-0.11px;}
#t1m_88{left:405px;bottom:492px;letter-spacing:-0.08px;word-spacing:-0.01px;}
#t1n_88{left:405px;bottom:473px;letter-spacing:-0.1px;}
#t1o_88{left:405px;bottom:455px;letter-spacing:-0.1px;}
#t1p_88{left:496px;bottom:463px;}
#t1q_88{left:405px;bottom:437px;letter-spacing:-0.08px;}
#t1r_88{left:405px;bottom:418px;letter-spacing:-0.1px;}
#t1s_88{left:544px;bottom:426px;}
#t1t_88{left:405px;bottom:368px;letter-spacing:-0.08px;}
#t1u_88{left:405px;bottom:350px;letter-spacing:-0.06px;}
#t1v_88{left:405px;bottom:331px;letter-spacing:-0.1px;}
#t1w_88{left:405px;bottom:313px;letter-spacing:-0.1px;}
#t1x_88{left:405px;bottom:295px;letter-spacing:-0.1px;}
#t1y_88{left:496px;bottom:302px;}
#t1z_88{left:405px;bottom:276px;letter-spacing:-0.06px;}
#t20_88{left:405px;bottom:258px;letter-spacing:-0.1px;}
#t21_88{left:544px;bottom:266px;}
#t22_88{left:825px;bottom:639px;letter-spacing:-0.1px;}
#t23_88{left:825px;bottom:621px;letter-spacing:-0.09px;}
#t24_88{left:825px;bottom:603px;letter-spacing:-0.08px;}
#t25_88{left:968px;bottom:564px;letter-spacing:-0.09px;}
#t26_88{left:968px;bottom:546px;letter-spacing:-0.09px;}
#t27_88{left:968px;bottom:528px;letter-spacing:-0.1px;}
#t28_88{left:968px;bottom:509px;letter-spacing:-0.09px;}
#t29_88{left:968px;bottom:491px;letter-spacing:-0.11px;}
#t2a_88{left:648px;bottom:451px;letter-spacing:-0.1px;}
#t2b_88{left:648px;bottom:431px;letter-spacing:-0.09px;}
#t2c_88{left:598px;bottom:174px;}
#t2d_88{left:607px;bottom:168px;letter-spacing:0.13px;}
#t2e_88{left:606px;bottom:151px;letter-spacing:0.12px;}
#t2f_88{left:606px;bottom:134px;letter-spacing:0.12px;}
#t2g_88{left:1053px;bottom:134px;letter-spacing:0.14px;}
#t2h_88{left:1158px;bottom:134px;}
#t2i_88{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_88{font-size:9px;font-family:ArialMT_5tg;color:#000;}
.s1_88{font-size:5px;font-family:ArialMT_5tg;color:#000;}
.s2_88{font-size:12px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_88{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_88{font-size:17px;font-family:ArialMT_5tg;color:#0065A4;}
.s5_88{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s6_88{font-size:12px;font-family:ArialMT_5tg;color:#000;}
.s7_88{font-size:15px;font-family:ArialMT_5tg;color:#0065A4;}
.s8_88{font-size:15px;font-family:ArialMT_5tg;color:#000;}
.s9_88{font-size:14px;font-family:Arial-BoldMT_5te;color:#000;}
.sa_88{font-size:17px;font-family:Arial-BoldMT_5te;color:#0065A4;}
.sb_88{font-size:15px;font-family:ArialMT_k0;color:#000;}
.sc_88{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts88" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

@font-face {
	font-family: ArialMT_k0;
	src: url("fonts/ArialMT_k0.woff") format("woff");
}

</style>
<div id="pg88Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg88" style="-webkit-user-select: none;"><object width="1210" height="935" data="88/88.svg" type="image/svg+xml" id="pdf88" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_88" class="t s0_88">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_88" class="t s1_88">® </span>
<span id="t3_88" class="t s0_88">(NCCN </span>
<span id="t4_88" class="t s1_88">® </span>
<span id="t5_88" class="t s0_88">), All rights reserved. NCCN Guidelines </span>
<span id="t6_88" class="t s1_88">® </span>
<span id="t7_88" class="t s0_88">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_88" class="t s2_88">Note: All recommendations are category 2A unless otherwise indicated. </span>
<span id="t9_88" class="t s2_88">Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. </span>
<span id="ta_88" class="t s3_88">NCCN Guidelines Version 4.2024 </span>
<span id="tb_88" class="t s3_88">Mucosal Melanoma </span>
<span id="tc_88" class="t s4_88">NCCN Guidelines Index </span>
<span id="td_88" class="t s4_88">Table of Contents </span>
<span id="te_88" class="t s4_88">Discussion </span>
<span id="tf_88" class="t s5_88">MM-3 </span>
<span id="tg_88" class="t s6_88">h </span>
<span id="th_88" class="t s7_88">Principles of Surgery (SURG-A)</span><span id="ti_88" class="t s8_88">. </span>
<span id="tj_88" class="t s6_88">i </span>
<span id="tk_88" class="t s7_88">Principles of Radiation Therapy (MM-A)</span><span id="tl_88" class="t s8_88">. </span>
<span id="tm_88" class="t s6_88">j </span>
<span id="tn_88" class="t s7_88">See Systemic Therapy for Metastatic or Unresectable Disease (ME-I) </span>
<span id="to_88" class="t s7_88">from the NCCN Guidelines for Melanoma: Cutaneous</span><span id="tp_88" class="t s8_88">. </span>
<span id="tq_88" class="t s5_88">Oral cavity, oropharynx, </span>
<span id="tr_88" class="t s5_88">larynx, or hypopharynx </span>
<span id="ts_88" class="t s5_88">mucosal melanoma </span>
<span id="tt_88" class="t s5_88">PRIMARY TREATMENT </span><span id="tu_88" class="t s5_88">ADJUVANT </span>
<span id="tv_88" class="t s5_88">TREATMENT </span>
<span id="tw_88" class="t s5_88">FOLLOW-UP </span>
<span id="tx_88" class="t s5_88">Resection </span>
<span id="ty_88" class="t s9_88">h </span>
<span id="tz_88" class="t s5_88">T3,N0 </span>
<span id="t10_88" class="t s5_88">Strongly consider </span>
<span id="t11_88" class="t s5_88">postoperative RT </span>
<span id="t12_88" class="t s9_88">i </span>
<span id="t13_88" class="t s5_88">± </span>
<span id="t14_88" class="t s5_88">Systemic therapy </span>
<span id="t15_88" class="t s5_88">(category 2B) </span>
<span id="t16_88" class="t s9_88">k </span>
<span id="t17_88" class="t s5_88">T3,N1 or </span>
<span id="t18_88" class="t s5_88">T4a,N0–1 </span>
<span id="t19_88" class="t s5_88">Clinical trial (preferred) </span>
<span id="t1a_88" class="t s5_88">or </span>
<span id="t1b_88" class="t s5_88">Resection </span>
<span id="t1c_88" class="t s5_88">± neck dissection </span>
<span id="t1d_88" class="t s9_88">h </span>
<span id="t1e_88" class="t s5_88">Postoperative RT </span>
<span id="t1f_88" class="t s9_88">i </span>
<span id="t1g_88" class="t s5_88">± </span>
<span id="t1h_88" class="t s5_88">Systemic therapy </span>
<span id="t1i_88" class="t s5_88">(category 2B) </span>
<span id="t1j_88" class="t s9_88">k </span>
<span id="t1k_88" class="t s5_88">T4b,N0 </span>
<span id="t1l_88" class="t s5_88">T4b,N1 </span>
<span id="t1m_88" class="t s5_88">Clinical trial (preferred) </span>
<span id="t1n_88" class="t s5_88">or </span>
<span id="t1o_88" class="t s5_88">Primary RT </span>
<span id="t1p_88" class="t s9_88">i </span>
<span id="t1q_88" class="t s5_88">and/or </span>
<span id="t1r_88" class="t s5_88">Systemic therapy </span>
<span id="t1s_88" class="t s9_88">j </span>
<span id="t1t_88" class="t s5_88">Clinical trial (preferred) </span>
<span id="t1u_88" class="t s5_88">or </span>
<span id="t1v_88" class="t s5_88">Best supportive care </span>
<span id="t1w_88" class="t s5_88">or </span>
<span id="t1x_88" class="t s5_88">Primary RT </span>
<span id="t1y_88" class="t s9_88">i </span>
<span id="t1z_88" class="t s5_88">or </span>
<span id="t20_88" class="t s5_88">Systemic therapy </span>
<span id="t21_88" class="t s9_88">j </span>
<span id="t22_88" class="t s5_88">Follow-up </span>
<span id="t23_88" class="t sa_88">(FOLL-A, 1 </span>
<span id="t24_88" class="t sa_88">of 2) </span>
<span id="t25_88" class="t s5_88">Recurrent or </span>
<span id="t26_88" class="t s5_88">persistent disease, </span>
<span id="t27_88" class="t sa_88">(NCCN Guidelines </span>
<span id="t28_88" class="t sa_88">for Melanoma: </span>
<span id="t29_88" class="t sa_88">Cutaneous) </span>
<span id="t2a_88" class="t sa_88">Post Systemic Therapy/RT or RT </span>
<span id="t2b_88" class="t sa_88">Neck Evaluation (FOLL-A, 2 of 2) </span>
<span id="t2c_88" class="t s6_88">k </span>
<span id="t2d_88" class="t s8_88">While adjuvant systemic therapy may be used for mucosal melanoma, data to </span>
<span id="t2e_88" class="t s8_88">support its use are far fewer than for cutaneous melanoma. Options may include </span>
<span id="t2f_88" class="t sb_88">nivolumab (category 2B) or cisplatin/temozolomide (category 2B). </span><span id="t2g_88" class="t s7_88">See Discussion</span><span id="t2h_88" class="t s8_88">. </span>
<span id="t2i_88" class="t sc_88">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
